Roche: EMA grants priority to spinal muscular atrophy drug
(CercleFinance.com) - Swiss pharma group Roche said that the European Medicines Agency (EMA) has granted priority review to its investigational oral medicine risdiplam for the treatment of spinal muscular atrophy.
Risdiplam, an orally administered gene splicing modifier, has shown improvements in motor function in people with this rare neuromuscular disorder, Roche said.
The so-called "Prime" designation by the EMA is granted to support development plans for promising medicines, accelerating their evaluation by the agency.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Risdiplam, an orally administered gene splicing modifier, has shown improvements in motor function in people with this rare neuromuscular disorder, Roche said.
The so-called "Prime" designation by the EMA is granted to support development plans for promising medicines, accelerating their evaluation by the agency.
Copyright (c) 2018 CercleFinance.com. All rights reserved.